Simponi, a subcutaneously administered anti-tumor necrosis factor therapy, has shown to induce clinical remission in ulcerative colitis patients.
More Articles on Gastroenterology:
PENTAX Launches Video Processor With PENTAX i-SCAN
SAGES Appoints Dr. Gerald Fried President
AGA Receives $1.5M Research Grant From Takeda Pharmaceuticals
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
